Cancer Research Microscope

Cue Biopharma Reports Two Objective Responses in First Interim Update from Dose Escalation Portion of Ongoing Phase 1 Study

Biotechnology Headlines Healthcare Investing What's Hot

Cue Biopharma, Inc. (NASDAQ: CUE) reported clinical update during yesterday’s conference call. According to the clinical-stage biopharmaceutical company reported early data in the combination study of CUE-101 and KEYTRUDA® (pembrolizumab) supports synergistic activity; of four patients treated in dose escalation in...

Advertisement